Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Tax Provisions (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Tax Provisions for 10 consecutive years, with $4000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Tax Provisions rose 33.33% to $4000.0 in Q4 2020 year-over-year; TTM through Sep 2021 was $4000.0, a 20.0% decrease, with the full-year FY2020 number at $5000.0, down 16.67% from a year prior.
  • Tax Provisions was $4000.0 for Q4 2020 at NovaBay Pharmaceuticals, up from $3000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $4000.0 in Q4 2020 to a low of $1000.0 in Q1 2017.
  • A 5-year average of $2111.1 and a median of $2000.0 in 2016 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: crashed 66.67% in 2016, then skyrocketed 100.0% in 2019.
  • NovaBay Pharmaceuticals' Tax Provisions stood at $2000.0 in 2016, then changed by 0.0% to $2000.0 in 2017, then skyrocketed by 50.0% to $3000.0 in 2018, then changed by 0.0% to $3000.0 in 2019, then skyrocketed by 33.33% to $4000.0 in 2020.
  • Per Business Quant, the three most recent readings for NBY's Tax Provisions are $4000.0 (Q4 2020), $3000.0 (Q4 2019), and $2000.0 (Q2 2019).